Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Pipeline Developments & Deals by Airway Therapeutics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AT-100

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Large molecule

            Recipient: Celonic

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 20, 2020

            Details:

            Based on the agreement, Celonic will be responsible for process optimization and GMP manufacturing of AT-100 for clinical study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AT-100

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 11, 2020

            Details:

            Airway is aiming to enter the clinic later this year with AT-100 as an investigational preventive treatment for the serious respiratory disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AT-100

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $15.5 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing January 08, 2020

            Details:

            This funding will enable clinical development of AT-100 (rhSP-D), while also supporting preclinical research in influenza, respiratory syncytial virus (RSV) and cystic fibrosis.